Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and for weight management (as Zepbound) in adults with obesity or overweight with at least one weight-related comorbidity
Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2
Semaglutide is a synthetic version of GLP-1 that has been modified to last longer in the body
For some people, other forms of treatment, such as antibiotics or topical medications, may be more appropriate
Focus on compound movements like squats, deadlifts, bench press, rows, and overhead press
We plan to elucidate this aspect in our next research to expand our understanding of the mechanism of action of semaglutide in obesity-related cognitive impairment